Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Vascular smooth muscle–specific YAP/TAZ deletion triggers aneurysm development in mouse aorta
Marycarmen Arévalo Martínez, Olivia Ritsvall, Joakim Armstrong Bastrup, Selvi Celik, Gabriel Jakobsson, Fatima Daoud, Christopher Winqvist, Anders Aspberg, Catarina Rippe, Lars Maegdefessel, Alexandru Schiopu, Thomas A. Jepps, Johan Holmberg, Karl Swärd, Sebastian Albinsson
Marycarmen Arévalo Martínez, Olivia Ritsvall, Joakim Armstrong Bastrup, Selvi Celik, Gabriel Jakobsson, Fatima Daoud, Christopher Winqvist, Anders Aspberg, Catarina Rippe, Lars Maegdefessel, Alexandru Schiopu, Thomas A. Jepps, Johan Holmberg, Karl Swärd, Sebastian Albinsson
View: Text | PDF
Research Article Cell biology Vascular biology

Vascular smooth muscle–specific YAP/TAZ deletion triggers aneurysm development in mouse aorta

  • Text
  • PDF
Abstract

Inadequate adaption to mechanical forces, including blood pressure, contributes to development of arterial aneurysms. Recent studies have pointed to a mechanoprotective role of YAP and TAZ in vascular smooth muscle cells (SMCs). Here, we identified reduced expression of YAP1 in human aortic aneurysms. Vascular SMC–specific knockouts (KOs) of YAP/TAZ were thus generated using the integrin α8–Cre (Itga8-Cre) mouse model (i8-YT-KO). i8-YT-KO mice spontaneously developed aneurysms in the abdominal aorta within 2 weeks of KO induction and in smaller arteries at later times. The vascular specificity of Itga8-Cre circumvented gastrointestinal effects. Aortic aneurysms were characterized by elastin disarray, SMC apoptosis, and accumulation of proteoglycans and immune cell populations. RNA sequencing, proteomics, and myography demonstrated decreased contractile differentiation of SMCs and impaired vascular contractility. This associated with partial loss of myocardin expression, reduced blood pressure, and edema. Mediators in the inflammatory cGAS/STING pathway were increased. A sizeable increase in SOX9, along with several direct target genes, including aggrecan (Acan), contributed to proteoglycan accumulation. This was the earliest detectable change, occurring 3 days after KO induction and before the proinflammatory transition. In conclusion, Itga8-Cre deletion of YAP and TAZ represents a rapid and spontaneous aneurysm model that recapitulates features of human abdominal aortic aneurysms.

Authors

Marycarmen Arévalo Martínez, Olivia Ritsvall, Joakim Armstrong Bastrup, Selvi Celik, Gabriel Jakobsson, Fatima Daoud, Christopher Winqvist, Anders Aspberg, Catarina Rippe, Lars Maegdefessel, Alexandru Schiopu, Thomas A. Jepps, Johan Holmberg, Karl Swärd, Sebastian Albinsson

×

Figure 11

SOX9 is induced and drives a program of chondrogenic differentiation in i8-YT-KO aortae.

Options: View larger image (or click on image) Download as PowerPoint
SOX9 is induced and drives a program of chondrogenic differentiation in ...
(A) Staining of abdominal aorta with Alcian blue (left) and with an antibody directed against aggrecan (middle and right) in consecutive sections. Areas that were blue overlapped with areas that stained positive for aggrecan in red. Our transcriptomic data sets indicated increased expression of the chondrogenic transcription factor Sox9, a known regulator of aggrecan. (B) We thus interrogated RNA-sequencing data with a panel of knockout-validated SOX9 target genes and found the panel to be increased at 2 weeks and 8 weeks. FC, fold change. (C) A larger panel of SOX9 target genes in cartilage was next overlaid with our 8-week proteomic data, and the SOX9-regulated proteins that increased >2-fold are listed. (D) Sox9 and aggrecan (Acan) correlate in our transcriptomic data sets across genotypes and over time. Correlations were also tested for i8-YT-KO mice and control (Ctrl) mice separately, and the R values of those tests are given in red and green. (E) RT-qPCR for Sox9, aggrecan (Acan), and versican (Vcan) confirmed upregulation in thoracic aortae (n ≥ 4). (F) Western blot data for SOX9 in thoracic and abdominal aortae (n ≥ 6). DAPI (blue) was used as nuclear stain. *P < 0.05; **P < 0.01; ***P < 0.001 by Wilcoxon’s signed-rank test (B), Spearman’s correlation (D), or 2-tailed Student’s t test (E and F [except for versican, 8 weeks in panel E, where Mann-Whitney was used]).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts